MCID: SHG001
MIFTS: 57

Shigellosis

Categories: Rare diseases, Infectious diseases, Gastrointestinal diseases

Aliases & Classifications for Shigellosis

MalaCards integrated aliases for Shigellosis:

Name: Shigellosis 12 76 53 59 55 3 15
Dysentery, Bacillary 44 73
Shigella Flexneri Infectious Disease 12
Shigella Boydii Infectious Disease 12
Shigella Sonnei Infectious Disease 12
Shigella Gastroenteritis 12
Bacillary Dysentery 12
Shigella Infections 73

Characteristics:

Orphanet epidemiological data:

59
shigellosis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Shigellosis

NIH Rare Diseases : 53 Shigellosis is a disease caused by a group of bacteria called Shigella. Shigella is very contagious. Shigella germs are present in the stools of infected individuals for up to two weeks after symptoms have resolved. Individuals may be exposed through direct contact with an infected person or through contaminated food, water (both drinking and recreational water), or surfaces. Though anyone can get shigellosis, young children are most at risk. Symptoms of shigellosis usually begin one to two days after exposure and include diarrhea, abdominal pain, and fever. In otherwise healthy individuals, the symptoms usually resolve in 5-7 days. Those with mild shigellosis may need only rest and self-care measures to avoid dehydration (drinking fluids and electrolyte solutions). For more severe cases, antibiotics may be prescribed though some cases of shigellosis have been found to be resistant to antibiotics. Laboratory tests can be performed to determine which antibiotics are likely to be effective in an individual case. Most people make a full recovery, though it may take several months for bowel habits to return to normal. Complications are rare but may include post-infectious arthritis, bloodstream infections, seizures, or hemolytic-uremic syndrome (HUS).

MalaCards based summary : Shigellosis, also known as dysentery, bacillary, is related to dysentery and marasmus. An important gene associated with Shigellosis is CASP1 (Caspase 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Anti-Bacterial Agents and Antibiotics, Antitubercular have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and t cells, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection located in epithelium of colon, has material basis in Shigella boydii, has material basis in Shigella dysenteriae, has material basis in Shigella flexneri, or has material basis in Shigella sonnei, which produce toxins that can attack the lining of the large intestine, causing swelling, ulcers on the intestinal wall, and bloody diarrhea. The bacteria are transmitted by ingestion of food and water contaminated with feces.

CDC : 3 Get Email Updates

Wikipedia : 76 Shigellosis is a type of diarrhea caused by a bacterial infection with Shigella. Symptoms generally... more...

Related Diseases for Shigellosis

Diseases related to Shigellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 dysentery 30.1 CD79A LTF TTR
2 marasmus 29.6 CD79A TTR
3 acute diarrhea 29.2 CD79A LTF
4 tetanus 29.0 CD79A IL10 LTA
5 meningitis 28.7 CXCL8 IL10 IRAK4
6 chlamydia 28.7 CASP1 CD79A CXCL8 IL10
7 israeli tick typhus 10.6 CASP1 CXCL8
8 streptococcal toxic-shock syndrome 10.6 CXCL8 LTA
9 exudative glomerulonephritis 10.5 CD79A CXCL8
10 tungiasis 10.5 CXCL8 IL10
11 acute transverse myelitis 10.4 CXCL8 IL10
12 erythema elevatum diutinum 10.4 CD79A CXCL8
13 scabies 10.4 CXCL8 IL10
14 neurosyphilis 10.4 CXCL8 IL10
15 carotenemia 10.4 CD79A TTR
16 mycobacterium marinum 10.4 CAMP CXCL8
17 wiskott-aldrich syndrome 10.4 CDC42 CTTN SRC
18 necatoriasis 10.4 CXCL8 IL10
19 vulvovaginitis 10.3 CXCL8 IL10
20 giant papillary conjunctivitis 10.3 CXCL8 LTF
21 blepharochalasis 10.3 CD79A TTR
22 funisitis 10.3 CXCL8 IL10
23 transient hypogammaglobulinemia 10.3 IL10 LTA
24 trichuriasis 10.2 CXCL8 IL10
25 root caries 10.2 CD79A LTF
26 trichomoniasis 10.1 CD79A CXCL8
27 salmonellosis 10.1
28 sporotrichosis 10.1 CD79A IL10
29 cholera 10.1
30 obstructive jaundice 10.1 CD79A CXCL8 TTR
31 haemophilus influenzae 10.1 CXCL8 LTF
32 idiopathic achalasia 10.1 IL10 LTA
33 parotitis 10.1 CD79A LTF
34 encephalopathy 10.1
35 tonsillitis 10.0 CD79A CXCL8 LTA
36 diarrhea 10.0
37 toxic shock syndrome 10.0 CXCL8 IL10 LTA
38 pouchitis 10.0 CXCL8 IL10 LTF
39 cow milk allergy 10.0 CD79A IL10
40 gingivitis 10.0 CD79A CXCL8 LTF
41 hemolytic-uremic syndrome 9.9
42 typhoid fever 9.9
43 clonorchiasis 9.9 CD79A CXCL8 IL10
44 nose disease 9.9 CD79A CXCL8 IL10
45 upper respiratory tract disease 9.9 CD79A CXCL8 IL10
46 extrinsic allergic alveolitis 9.9 CD79A CXCL8 IL10
47 bone inflammation disease 9.9 CD79A CXCL8 IL10
48 intestinal disease 9.9 CD79A CXCL8 IL10
49 hepatitis 9.9
50 mucositis 9.9

Graphical network of the top 20 diseases related to Shigellosis:



Diseases related to Shigellosis

Symptoms & Phenotypes for Shigellosis

MGI Mouse Phenotypes related to Shigellosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 CD79A CTTN IL10 IRAK4 LTF PFN1
2 hematopoietic system MP:0005397 9.65 CTTN IL10 IRAK4 LTA LTF PFN1
3 immune system MP:0005387 9.32 CTTN IL10 IRAK4 LTA LTF PFN1

Drugs & Therapeutics for Shigellosis

Drugs for Shigellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
2 Antibiotics, Antitubercular Phase 4,Phase 2,Not Applicable
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Acidophilus Nutraceutical Phase 4,Not Applicable
5
Zinc Approved, Investigational Phase 3 7440-66-6 23994
6
Rifaximin Approved, Investigational Phase 3 80621-81-4 6436173
7 Antibodies Phase 3
8 Immunoglobulins Phase 3
9 Vaccines Phase 3,Phase 1,Phase 2,Not Applicable
10 Micronutrients Phase 3
11 Trace Elements Phase 3
12 Gastrointestinal Agents Phase 3,Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 3
14 rifamycin SV Phase 3
15 Rifamycins Phase 3
16 Shiga Toxins Phase 3
17
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
18
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
19 Histamine Antagonists Phase 2
20
Histamine Phosphate Phase 2 51-74-1 65513
21 Neurotransmitter Agents Phase 2
22 Pharmaceutical Solutions Phase 2
23
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
24
Aluminum sulfate Approved Phase 1 10043-01-3
25 Adjuvants, Immunologic Phase 1
26 Antacids Phase 1
27 Anti-Ulcer Agents Phase 1
28
Formaldehyde Approved, Vet_approved 50-00-0 712
29 Disinfectants ,Not Applicable
30 Ether
31 Antitubercular Agents Not Applicable
32 Complement System Proteins
33 Bifidobacterium Nutraceutical Not Applicable

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial Completed NCT02871908 Phase 4 Lactobacillus reuteri DSM 17938;Placebo
2 Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Completed NCT00368316 Phase 3
3 Zinc Supplementation in Shigella Patients Completed NCT00321126 Phase 3 Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.
4 Rifaximin for Prevention of Travellers' Diarrhea Completed NCT00742469 Phase 3 Rifaximin;Placebo
5 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia Recruiting NCT03362970 Phase 3
6 Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Completed NCT00485134 Phase 1, Phase 2
7 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
8 Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Completed NCT02646371 Phase 2
9 A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults Completed NCT02676895 Phase 2
10 Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine Completed NCT00210288 Phase 2
11 Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate Completed NCT01080716 Phase 1, Phase 2
12 Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults Completed NCT02669121 Phase 2
13 A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults Not yet recruiting NCT03527173 Phase 2 GAHB-Placebo
14 Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb Terminated NCT00866242 Phase 2
15 Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa Terminated NCT00866476 Phase 2
16 Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults Withdrawn NCT03038243 Phase 2
17 Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Completed NCT01369927 Phase 1
18 Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP Completed NCT01531530 Phase 1
19 Shigella Sonnei 53G Challenge Completed NCT02816346 Phase 1
20 A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. Completed NCT02017899 Phase 1
21 Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Completed NCT02034500 Phase 1
22 Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Completed NCT01509846 Phase 1
23 Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Completed NCT01069471 Phase 1
24 Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 Completed NCT01336699 Phase 1
25 Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Completed NCT02388009 Phase 1
26 A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study Completed NCT03089879 Phase 1
27 Shigella WRSS1 Vaccine Trial in Bangladesh Completed NCT02934178 Phase 1
28 Invaplex 50 Vaccine Dose-Ranging Completed NCT00082069 Phase 1
29 SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers Completed NCT02797236 Phase 1
30 Effect of 15g Daily Consumption of NUTRIOSE on Healthy Volunteers Microbiota. Completed NCT01897649 Phase 1
31 Phase 1 Study of dmLT ID Vaccination in Healthy Adults Recruiting NCT02531685 Phase 1
32 Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers Active, not recruiting NCT02445963 Phase 1
33 Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months Active, not recruiting NCT03561181 Phase 1
34 Shigella Sonnei OSPC-rDT Conjugate Vaccine Withdrawn NCT01399424 Phase 1 CP
35 Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections Unknown status NCT01638039 Not Applicable
36 A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals Unknown status NCT01612572
37 Experimental Phage Therapy of Bacterial Infections Unknown status NCT00945087 Not Applicable
38 The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study Completed NCT02516683
39 Safety Study of Live Shigella Vaccine in Bangladeshi Adults and Children Completed NCT01813071 Not Applicable
40 Evaluation of a Diagnostic Enteric Card for Management of Diarrhea Completed NCT00736567
41 Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders Completed NCT02105714
42 SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance Recruiting NCT03313128
43 Explanations for Negative Laparoscopic Appendectomies and Normal Laparoscopies Recruiting NCT03349814
44 Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital Recruiting NCT03261297
45 The Effect of an Urban Sanitation Intervention on Child Health Recruiting NCT02362932 Not Applicable
46 The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children. Recruiting NCT03334604 Not Applicable
47 Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases Recruiting NCT01945307
48 COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk) Recruiting NCT02839317
49 Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy Recruiting NCT02709213
50 The Safe Start Trial - Kisumu, Kenya Recruiting NCT03468114 Not Applicable

Search NIH Clinical Center for Shigellosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dysentery, bacillary

Genetic Tests for Shigellosis

Anatomical Context for Shigellosis

MalaCards organs/tissues related to Shigellosis:

41
Colon, Testes, T Cells, Brain, Kidney, Neutrophil, Appendix

The Foundational Model of Anatomy Ontology organs/tissues related to Shigellosis:

19
Epithelium Of Colon

Publications for Shigellosis

Articles related to Shigellosis:

(show top 50) (show all 566)
# Title Authors Year
1
Shigellosis and toxic megacolon secondary to Shigella flexneri serotype 3a: The challenges of laboratory diagnosis. ( 29501836 )
2018
2
An adult case with shigellosis-associated encephalopathy. ( 29351935 )
2018
3
Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis. ( 29960802 )
2018
4
50 Years Ago in The Journal of Pediatrics: Comparison of Orally Absorbable and Nonabsorbable Antibiotics in Shigellosis: A Double-Blind Study with Ampicillin and Neomycin. ( 29703354 )
2018
5
Shigella (Shigellosis) ( 29493962 )
2018
6
Shigellosis outbreak among MSM living with HIV: a case-control study in Taiwan, 2015-2016. ( 29535222 )
2018
7
Microevolution and Patterns of Transmission of Shigella sonnei within Cyclic Outbreaks Shigellosis, Israel. ( 29912703 )
2018
8
Heavy precipitation as a risk factor for shigellosis among homeless persons during an outbreak - Oregon, 2015-2016. ( 29217465 )
2018
9
Prediction of Shigellosis outcomes in Israel using machine learning classifiers. ( 29880081 )
2018
10
Investigating the Geographic Distribution of Shigellosis Among Men and Women in Massachusetts: Possible Implications for Men Who Have Sex With Men. ( 29420446 )
2018
11
Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence. ( 29790845 )
2018
12
Disparities in severe shigellosis among adults - Foodborne diseases active surveillance network, 2002-2014. ( 29415691 )
2018
13
Whole-genome sequencing revealed concurrent outbreaks of shigellosis in the English Orthodox Jewish Community caused by multiple importations of Shigella sonnei from Israel. ( 29583113 )
2018
14
Importation of travel-related infectious diseases is increasing in South Korea: An analysis of salmonellosis, shigellosis, malaria, and dengue surveillance data. ( 28919170 )
2017
15
Protection against shigellosis caused by Shigella dysenteriae serotype 4 in guinea pigs using Escherichia albertii DM104 as a live vaccine candidate strain. ( 28597684 )
2017
16
What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission? ( 28490580 )
2017
17
Shigellosis Caused by CTX-M Type ESBL Producing Shigella flexneri in Two Siblings of Rural Nepal: First Case Report from the Country. ( 28321350 )
2017
18
A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against<i>Shigella sonnei</i>Administered Intramuscularly to Adults from a Shigellosis-Endemic Country. ( 29375556 )
2017
19
Seasonal and geographical distribution of bacillary dysentery (shigellosis) and associated climate risk factors in Kon Tam Province in Vietnam from 1999 to 2013. ( 28637484 )
2017
20
Brugada syndrome revealed by intestinal shigellosis in a patient from Benin at the University Hospital of Saint-Etienne. ( 28944419 )
2017
21
Shigellosis. ( 29256205 )
2017
22
Double-stranded RNA induces cathelicidin expression in the intestinal epithelial cells through phosphatidylinositol 3-kinase-protein kinase CIP-Sp1 pathway and ameliorates shigellosis in mice. ( 28343946 )
2017
23
50 Years Ago in The Journal of Pediatrics: Double-Blind Treatment Study of Shigellosis Comparing Ampicillin, Sulfadiazine, and Placebo. ( 28746042 )
2017
24
An 11-year study of shigellosis and Shigella species in Taiyuan, China: Active surveillance, epidemic characteristics, and molecular serotyping. ( 28188118 )
2017
25
Shigellosis. ( 29254859 )
2017
26
An outbreak of shigellosis in a Children Welfare Institute caused by a multiple-antibiotic-resistant strain of Shigella flexneri 2a. ( 28189512 )
2017
27
Correspondence to invasive shigellosis in MSM. ( 28125923 )
2017
28
Shigellosis and Pregnancy in French Guiana: Obstetric and Neonatal Complications. ( 27114299 )
2016
29
Shigellosis in men who have sex with men: an overlooked opportunity to counsel with pre-exposure prophylaxis for HIV. ( 26945593 )
2016
30
Shigellosis. ( 27556171 )
2016
31
Shigellosis murine model established by intraperitoneal and intranasal route of administration: a comparative comprehension overview. ( 27664045 )
2016
32
A review of the public health management of shigellosis in Australia in the era of culture-independent diagnostic testing. ( 27774718 )
2016
33
A Synthetic Carbohydrate Conjugate Vaccine Candidate against Shigellosis: Improved Bioconjugation and Impact of Alum on Immunogenicity. ( 26918643 )
2016
34
Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection Against Shigellosis in a Controlled Human Challenge Study. ( 27927680 )
2016
35
Long-term Clinical Course of Post-infectious Irritable Bowel Syndrome after Shigellosis: A 10-year Follow-up Study. ( 26908484 )
2016
36
Molecular Evaluation of High Fluoroquinolone Resistant Genes in Endemic Cases of Shigellosis, Northeast Part of Karnataka, India. ( 28283137 )
2016
37
Recent Outbreaks of Shigellosis in California Caused by Two Distinct Populations of Shigella sonnei with either Increased Virulence or Fluoroquinolone Resistance. ( 28028547 )
2016
38
True Prevalence of Shigellosis in Indian Children with Acute Gastroenteritis: Have We Been Missing the Diagnosis? ( 27061990 )
2016
39
Shigellosis in Nepal: 13A years review of nationwide surveillance. ( 27814742 )
2016
40
Molecular Characterization of Shigella sonnei: An Increasingly Prevalent Etiologic Agent of Shigellosis in Guizhou Province, Southwest of China. ( 27195892 )
2016
41
Development of a live attenuated bivalent oral vaccine against Shigella sonnei shigellosis and typhoid fever. ( 27803169 )
2016
42
Shigellosis: Epidemiology in India. ( 27487999 )
2016
43
Shigellosis: high rates of antibiotic resistance necessitate new treatment recommendations. ( 27078594 )
2016
44
Notes from the Field: Shigellosis Outbreak Among Men Who Have Sex with Men and Homeless Persons - Oregon, 2015-2016. ( 27513523 )
2016
45
Invasive shigellosis in MSM. ( 26429891 )
2015
46
Disparities of Shigellosis Rates among California Children by Race/Ethnicity and Census Tract Poverty Level, 2000-2010. ( 26020406 )
2015
47
Fulminant Shigellosis in a HIV Patient. ( 25821609 )
2015
48
Microbiota that affect risk for shigellosis in children in low-income countries. ( 25625766 )
2015
49
Shigellosis Outbreak in Al Batinah South Governorate, Oman: Case-control study. ( 26357558 )
2015
50
Shigella Infections in Household Contacts of Pediatric Shigellosis Patients in Rural Bangladesh. ( 26484778 )
2015

Variations for Shigellosis

Expression for Shigellosis

Search GEO for disease gene expression data for Shigellosis.

Pathways for Shigellosis

Pathways related to Shigellosis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 CAMP CASP1 CD79A CDC42 CRK CXCL8
2
Show member pathways
13.17 CASP1 CRK CXCL8 IL10 IRAK4 LTA
3
Show member pathways
12.99 CASP1 CDC42 CRK CXCL8 IL10 LTA
4
Show member pathways
12.9 CAMP CASP1 CXCL8 IL10 IRAK4
5
Show member pathways
12.72 CDC42 CRK CTTN PFN1 SRC
6
Show member pathways
12.54 CDC42 CTTN SRC VCL
7
Show member pathways
12.49 CDC42 CRK PFN1 SRC VCL
8 12.45 CDC42 CRK PFN1 SRC VCL
9
Show member pathways
12.43 CDC42 CTTN PFN1 SRC
10 12.43 CDC42 CTTN PFN1 VCL
11
Show member pathways
12.36 CASP1 IRAK4 LTA SRC
12
Show member pathways
12.33 CDC42 CRK IRAK4 SRC
13
Show member pathways
12.3 CDC42 CRK SRC VCL
14 12.1 CAMP IL10 IRAK4 SRC
15
Show member pathways
11.97 CASP1 CXCL8 IL10 SRC
16
Show member pathways
11.88 CDC42 CRK SRC
17 11.79 CXCL8 IL10 VCL
18 11.78 CXCL8 IRAK4 LTA
19
Show member pathways
11.76 CDC42 SRC VCL
20 11.67 CASP1 CDC42 CXCL8 PFN1
21 11.64 CDC42 SRC VCL
22 11.59 CDC42 IRAK4 SRC
23 11.57 CRK CXCL8 SRC
24 11.55 CASP1 CXCL8 IL10 IRAK4
25 11.5 CDC42 CTTN SRC
26 11.48 CRK SRC VCL
27 11.46 CDC42 CRK SRC
28 11.29 CDC42 CTTN SRC
29 11.22 CDC42 CRK CTTN SRC VCL
30 11.08 CDC42 CRK CTTN SRC
31 11.05 CDC42 CRK SRC
32 10.98 CDC42 CRK CTTN CXCL8 PFN1 SRC
33 10.81 CTTN CXCL8 SRC

GO Terms for Shigellosis

Cellular components related to Shigellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 CAMP CDC42 CRK CTTN LTF PFN1
2 focal adhesion GO:0005925 9.76 CDC42 CTTN PFN1 VCL
3 extracellular space GO:0005615 9.76 CAMP CXCL8 IL10 IRAK4 LTA LTF
4 specific granule GO:0042581 9.43 CAMP LTF
5 specific granule lumen GO:0035580 9.43 CAMP LTF VCL
6 podosome GO:0002102 9.13 CTTN SRC VCL
7 protein-containing complex GO:0032991 9.1 CASP1 CDC42 CRK LTF TTR VCL
8 cytoplasm GO:0005737 10.15 CAMP CASP1 CD79A CDC42 CRK CTTN
9 extracellular region GO:0005576 10.01 CAMP CASP1 CXCL8 IL10 LTA LTF

Biological processes related to Shigellosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.65 CDC42 CRK SRC
2 cytokine-mediated signaling pathway GO:0019221 9.65 CASP1 CRK CXCL8 IL10 IRAK4
3 response to lipopolysaccharide GO:0032496 9.62 CASP1 CXCL8 IL10 LTA
4 ephrin receptor signaling pathway GO:0048013 9.58 CDC42 CRK SRC
5 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.54 CDC42 CRK SRC
6 regulation of protein binding GO:0043393 9.49 CRK SRC
7 positive regulation of smooth muscle cell migration GO:0014911 9.46 CRK SRC
8 response to molecule of bacterial origin GO:0002237 9.43 CXCL8 IL10
9 positive regulation of cytokine secretion GO:0050715 9.33 CASP1 IL10 SRC
10 negative regulation of growth of symbiont in host GO:0044130 9.13 CAMP IL10 LTA
11 cellular response to lipopolysaccharide GO:0071222 9.02 CAMP CASP1 CXCL8 IL10 SRC

Molecular functions related to Shigellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 CASP1 CD79A CDC42 CRK CTTN CXCL8
2 cadherin binding GO:0045296 8.92 CTTN PFN1 SRC VCL

Sources for Shigellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....